YAP1 and renal cell carcinoma: Some small‐molecule inhibitors, such as dasatinib, along with statins and topoisomerase inhibitor A35, acted as effective YAP1 inhibitors in renal cell carcinoma and pancreatic cancer,17 while their effects on YAP1 were found to be nonspecific and indirect.15